Advertisement

Advertisement

News

Vedotin Antibody-Drug Conjugate: Focus of First-in-Human Study in Advanced Solid Tumors

News

Final Phase III Trial Results of Trastuzumab Duocarmazine in Metastatic Breast Cancer

News

Doubling Up on Antibody-Drug Conjugates in Metastatic Urothelial Carcinoma

News

Do All Subtypes of Triple-Negative Breast Cancer Respond to Atezolizumab?

Medical Literature

Can a Novel Scoring System Predict Outcomes With CAR T-Cell Therapy for Myeloma?

Medical Literature

Biological Mechanisms Behind Immune Checkpoint Inhibitors in Bladder Cancer

News

Can Health of the Immune System Help Predict the Duration of Remission in Myeloma?

Thomas Powles, MD, PhD: A Look Into the Future of Kidney Cancer Treatment

Heinz-Josef Lenz, MD, on Reducing Ipilimumab Dose: What Are the Ramifications?

View More

Advertisement

JNCCN Spotlights

Cetuximab (Head and Neck Cancers)

View More

More

News

On-Treatment ctDNA Measurements and Immunotherapy Response in Urothelial Cancer

Can Health of the Immune System Help Predict the Duration of Remission in Myeloma?

ESMO 2023: KEYNOTE-522 Update on Use of Pembrolizumab in Triple-Negative Breast Cancer

ESMO 2023: EV-302 Update on Immunotherapy Combination in Advanced Urothelial Cancer

Can Radiotherapy Prime Immune System in Oligometastatic Prostate Cancer?

Atezolizumab Plus Bevacizumab After Surgery for High-Risk Liver Cancer: Phase III Results

ESMO 2023: DESTINY-Breast04 Survival Update on T-DXd in HER2-Low Breast Cancer

Vedotin Antibody-Drug Conjugate: Focus of First-in-Human Study in Advanced Solid Tumors

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Similarities and Differences in the Efficacy of Neoadjuvant and Adjuvant Immunotherapies for Localized NSCLC

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Minimizing the Impact of imAEs and Maximizing Efficacy of ICIs: AEs Affecting the Skin

View More

Available

Clinical Trials

A Study to Learn About the Effects of the Combination of Elranatamab

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced NSCLC

A Phase III, Randomized, Placebo-Controlled Clinical Study of SBRT With or Without Pembrolizumab in Participants With Medically Inoperable NSCLC (KEYNOTE-867)

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.